drugset / Trial / NCT06669143
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
NaSingle-groupOpen-labelTreatment
Summary
This single-arm, prospective clinical study will evaluate the efficacy and safety of Zanubrutinib-based maintenance therapy for post-remission in newly diagnosed DLBCL who are intolerant to first-line intensive chemotherapy.
Timeline
- Start
- 2024-11
- Primary completion
- 2026-11
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |